From Yahoo Finance: 2025-06-23 01:40:00

Twist Bioscience Corporation (NASDAQ:TWST) has expanded its partnership with Element Biosciences to provide end-to-end Next Generation Sequencing (NGS) solutions, making it one of the 11 best genomics stocks to buy according to Hedge Funds. This collaboration integrates Twist’s library prep and target enrichment workflows with Element’s AVITI™ devices and Trinity™ flowcells, with Twist being the sole supplier of the new Trinity kits for the AVITI platform. The companies will work together to enhance customer access to high-performance NGS technologies.

This expanded relationship builds on Twist Bioscience Corporation’s past success, including the Trinity solution for quick hybridization. The partnership aims to streamline hybrid capture for agbio, genomics, and clinical research by optimizing workflows both off and on sequencers. Twist CEO Emily Leproust emphasizes that this collaboration will provide researchers with improved platform flexibility, uniformity, and quality by extending NGS capabilities beyond exome sequencing.

Element Biosciences CEO Molly He underscores the importance of combining Twist Bioscience Corporation’s prep capabilities with Trinity’s focused sequencing to advance scientific research. The partnership aims to enhance platform flexibility, uniformity, and quality for researchers by extending NGS capabilities beyond exome sequencing. This collaboration is crucial for advancing science and improving workflows in various research fields.



Read more at Yahoo Finance: Twist and Element Biosciences Expands Pact for Sequencing Workflow Solutions